Opendata, web and dolomites

BIOMAP SIGNED

Biomarkers in Atopic Dermatitis and Psoriasis

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 BIOMAP project word cloud

Explore the words cloud of the BIOMAP project. It provides you a very rough idea of what is the project "BIOMAP" about.

comorbidity    manifestation    predictive    time    dimensional    mathematical    clinically    mechanism    trial    whom    re    pass    single    our    shorten    medicine    create    infrastructure    unprecedented    modification    assay    blood    quality    biology    psoriasis    relative    trajectory    trajectories    atopic    biomarkers    minimize    accessible    dermatitis    diagnostics    profiling    taxonomic    population    flexible    strategies    endotypes    signatures    data    silico    datasets    epidemiology    annotated    discriminatory    diagnosis    systematically    intervene    subpopulations    disease    cell    paradigm    prevention    skin    pro    causal    harmonizing    clinical    risk    diverse    supplementary    interact    portal    matching    environmental    biospecimen    determinants    resource    model    therapeutics    material    progression    life    treatment    molecular    drug    translation    central    outcomes    ready    drive    discovery    fundamentally    biomap    intervention    lifestyle    patient    pipeline    parallel    shared    active    mechanisms   

Project "BIOMAP" data sheet

The following table provides information about the project.

Coordinator
CHRISTIAN-ALBRECHTS-UNIVERSITAET ZU KIEL 

Organization address
address: OLSHAUSENSTRASSE 40
city: KIEL
postcode: 24118
website: http://www.uni-kiel.de

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 20˙884˙846 €
 EC max contribution 10˙499˙999 € (50%)
 Programme 1. H2020-EU.3.1.7. (Innovative Medicines Initiative 2 (IMI2))
 Code Call H2020-JTI-IMI2-2017-13-two-stage
 Funding Scheme IMI2-RIA
 Starting year 2019
 Duration (year-month-day) from 2019-04-01   to  2024-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CHRISTIAN-ALBRECHTS-UNIVERSITAET ZU KIEL DE (KIEL) coordinator 1˙535˙000.00
2    KING'S COLLEGE LONDON UK (LONDON) participant 1˙567˙007.00
3    UNIVERSITY OF BRISTOL UK (BRISTOL) participant 647˙437.00
4    KAROLINSKA INSTITUTET SE (STOCKHOLM) participant 599˙032.00
5    EURICE EUROPEAN RESEARCH AND PROJECT OFFICE GMBH DE (ST INGBERT) participant 556˙750.00
6    DEN SELVEJENDE INSTITUTION DANSK BORNEASTMA CENTER DK (GENTOFTE) participant 544˙118.00
7    UNIVERSITE DU LUXEMBOURG LU (ESCH-SUR-ALZETTE) participant 488˙936.00
8    AIT AUSTRIAN INSTITUTE OF TECHNOLOGY GMBH AT (WIEN) participant 466˙711.00
9    INFORMATION TECHNOLOGY FOR TRANSLATIONAL MEDICINE (ITTM) SA LU (Esch-sur-Alzette) participant 460˙360.00
10    TAMPEREEN KORKEAKOULUSAATIO SR FI (TAMPERE) participant 415˙801.00
11    ACADEMISCH ZIEKENHUIS LEIDEN NL (LEIDEN) participant 410˙937.00
12    KLINIKUM RECHTS DER ISAR DER TECHNISCHEN UNIVERSITAT MUNCHEN DE (MUENCHEN) participant 376˙250.00
13    KOBENHAVNS UNIVERSITET DK (KOBENHAVN) participant 274˙500.00
14    STICHTING KATHOLIEKE UNIVERSITEIT NL (NIJMEGEN) participant 258˙500.00
15    HEINRICH-HEINE-UNIVERSITAET DUESSELDORF DE (DUSSELDORF) participant 221˙625.00
16    UNIVERSITAT WIEN AT (WIEN) participant 208˙350.00
17    LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE ROYAL CHARTER UK (LONDON) participant 203˙250.00
18    UNIVERSITY OF DUNDEE UK (DUNDEE) participant 196˙062.00
19    TARTU ULIKOOL EE (TARTU) participant 193˙500.00
20    TECHNISCHE UNIVERSITAET MUENCHEN DE (MUENCHEN) participant 185˙000.00
21    ITA-SUOMEN YLIOPISTO FI (KUOPIO) participant 175˙125.00
22    ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM NL (AMSTERDAM) participant 161˙875.00
23    HAHN-SCHICKARD-GESELLSCHAFT FUER ANGEWANDTE FORSCHUNG E.v. DE (Villingen) participant 149˙625.00
24    CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS CH (LAUSANNE) participant 81˙250.00
25    UNIVERSITAETSKLINIKUM HAMBURG-EPPENDORF DE (HAMBURG) participant 63˙125.00
26    THE PROVOST, FELLOWS, FOUNDATION SCHOLARS & THE OTHER MEMBERS OF BOARD OF THE COLLEGE OF THE HOLY & UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN IE (DUBLIN) participant 59˙870.00
27    BOEHRINGER INGELHEIM INTERNATIONALGMBH DE (INGELHEIM) participant 0.00
28    LEO PHARMA AS DK (BALLERUP) participant 0.00
29    PFIZER LIMITED UK (SANDWICH) participant 0.00
30    SANOFI-AVENTIS DEUTSCHLAND GMBH DE (FRANKFURT AM MAIN) participant 0.00
31    TAMPEREEN YLIOPISTO FI (TAMPERE) participant 0.00
32    UCB BIOPHARMA SRL BE (BRUXELLES) participant 0.00

Map

 Project objective

Our objective is to provide a taxonomic and predictive systems medicine model of Atopic Dermatitis and Psoriasis based on clinical and molecular profiling to (i) identify determinants of clinically relevant outcomes (disease manifestation, progression, comorbidity development and treatment response) (ii) improve understanding on shared and distinct disease mechanism(s) and associated signatures, and their relative importance in patient subpopulations and (iii) deliver biomarkers that identify disease trajectories and treatment response for use in drug development and clinical practice. BIOMAP will create a biospecimen and data resource of unprecedented scale and depth, accessible via a central data and analysis portal, harmonizing diverse, high quality, multi-dimensional datasets on skin and blood (whole and single cell), large scale population-based and trial data; parallel clinical research infrastructure will deliver supplementary material flexible to the needs of the consortium. This resource will be systematically analyzed using state-of-the-art methodologies in epidemiology, molecular profiling, skin biology and mathematical modelling to define disease and drug endotypes and how these interact with lifestyle and environmental factors. Selected, highly discriminatory, associated biomarkers will pass through a diagnostics pipeline (novel in-silico trial methods and assay development), ready for immediate translation. BIOMAP is expected to drive drug discovery to target causal mechanisms, shorten drug development pathways, and fundamentally change the diagnosis and management paradigm, from re-active to pro-active strategies that encompass disease biology and life-time trajectory, matching the intervention (prevention, modification of risk factors, therapeutics) with endotypes. Clinically annotated endotypes and associated biomarkers will identify when, in whom and how to intervene to minimize disease impact and improve outcomes.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BIOMAP" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BIOMAP" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.7.)

RespiriNTM (2019)

Progress novel assets (one FIH start) for non-tubercular mycobacteria that may act synergistically with bedaquiline and cytochrome bc drugs

Read More  

EBOVAC3 (2018)

Bringing a prophylactic Ebola vaccine to licensure

Read More  

GNA NOW (2019)

NOVEL GRAM-NEGATIVE ANTIBIOTIC NOW

Read More